gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Fibrinogen alpha chain

Fibrinopeptide A
plays a role in blood coagulation; may be involved in liver regeneration [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: HAD, Plasminogen, beta-Thromboglobulin, CAN, ACID
Papers on Fibrinopeptide A
Expression of a new serine protease from Crotalus durissus collilineatus venom in Pichia pastoris and functional comparison with the native enzyme.
Arantes et al., Ribeirão Preto, Brazil. In Appl Microbiol Biotechnol, Dec 2015
The native and recombinant enzymes showed similar effects upon bovine fibrinogen by releasing preferentially fibrinopeptide A. Although both enzymes have induced plasma coagulation, native Colinein-1 has shown higher coagulant activity.
Proteomic study of pilocytic astrocytoma pediatric brain tumor intracystic fluid.
Desiderio et al., Roma, Italy. In J Proteome Res, 2014
Top-down approach allowed to identify several proteins and peptides involved in different biological activities together with the characterization of interesting proteoforms such as fibrinopeptide A and its truncated form, fibrinopeptide B, complement C3f fragments, β-thymosin peptides, ubiquitin, several apolipoproteins belonging to A and C families, apolipoprotein J and D, and cystatin C. Of particular interest resulted the identification of a N-terminal truncated cystatin C proteoform, likely involved in immune response mechanism modulations and the identification of oxidized and glycosylated apolipoproteins including disulfide bridge dimeric forms.
[Effect of activating blood circulation or activating blood circulation and detoxication on platelet activation, inflammation, and coagulation status in acute myocardial infarction rats].
Shi et al., Beijing, China. In Zhongguo Zhong Xi Yi Jie He Za Zhi, 2014
Tumor necrosis factor-α (TNF-α), β-thromboglobulin (β-TG), platelet α granule membrane protein-140 (GMP-140), 11 dehydro-thromboxane B2 (11-DH-TXB2), fibrinopeptide A (FPA), antithrombin III (AT-III), and D-dimer (DD) were detected by ELISA.
Relevance of fibrinolytic protein (D-dimer) and fibrinopeptide A as markers of sickle cell anaemia vaso-occlusive crisis.
Ogunro et al., In Niger Postgrad Med J, 2014
AIMS AND OBJECTIVES: To determine the plasma concentration of fibrinolytic protein (D-dimer) and Fibrinopeptide A(FPA) in sickle cell anaemia (SCA) patients in steady state and vaso-occlusive crisis(VOC) for the purpose of determining their clinical value in assessing/or predicting the onset of VOC Subjects and Methods: A total of 25 (14 Males: 11Females) HbSS subjects in VOC , 24 (13M:11F) HbSS subjects in steady state between the ages of 10-40 years old and 30 (17M:13F) healthy HbAA volunteers, of the same age and sex with the subjects were recruited for the study.
Thrombin Generation among Sudanese Patients with Hematological Malignancies.
Babiker et al., Al Qurayyāt, Saudi Arabia. In Gulf J Oncolog, 2014
UNLABELLED: Hematological malignancies can change the levels of plasma molecules involved in coagulation and fibrinolysis such as fibrinopeptide A, fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and D-dimer, markers of endothelial cell integrity (soluble E-selectin, van Willebrand factor and soluble thromboembolism) and of platelet function (beta-thromboglobulin).
Translational success stories: development of direct thrombin inhibitors.
Hirsh et al., Hamilton, Canada. In Circ Res, 2012
Key events that facilitated the subsequent development of small molecule active site inhibitors, such as argatroban, were the observation that fibrinopeptide A had antithrombotic properties and determination of the crystal structure of thrombin.
Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury.
Vaidya et al., Boston, United States. In Am J Pathol, 2012
These results suggest that immunoreactivity of Fg in the kidney, as well as urinary excretion of Fg, serves as a sensitive and early diagnostic translational biomarker for detection of acute kidney injury.
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.
Favaloro et al., Parma, Italy. In J Thromb Thrombolysis, 2010
This article aims to review the pathophysiology and clinical usefulness of past, present and future markers of thrombosis, including soluble fibrin monomers, fibrin/fibrinogen degradation products, thrombin-antithrombin complex, plasmin-antiplasmin complex, fibrinopeptide A and B, prothrombin fragments 1 + 2, thrombus precursor protein, D-dimer, activated protein C-protein C inhibitor complex, myeloperoxidase, thrombin generation assays and proteomic analysis.
The coagulation system changes in patients with chronic heart failure.
Kasauskas et al., Kaunas, Lithuania. In Medicina (kaunas), 2009
It is proved that it causes the disorders of the coagulation system: an increase in the following factors of plasma coagulation (fibrinogen, VII, VIII, fibrinopeptide A, thrombin-antithrombin complex), fibrinolysis (D-dimer), endothelium (interleukin 1, endothelin 1, vascular cell adhesion molecules, endothelial growth factor), platelet activity (von Willebrand factor, intercellular adhesion molecules, platelet factor 4, P-selectin, thromboxane A(2), thromboglobulin, CD63P) and cytokines (tumor necrosis factor, interleukin 6) and decrease in E-selectin.
Eu-chelate anti-fibrin antibody-conjugated perfluorocarbon nanoparticles
Zhang, Bethesda, United States. In Unknown Journal, 2008
Fibrin is formed after thrombin cleavage of fibrinopeptide A from fibrinogen Aα-chains, followed by polymerization and cross-linkage to form thick fibrin bundles and complex, branched-clot networks (8).
Zhang, Bethesda, United States. In Unknown Journal, 2007
Fibrin is formed after thrombin cleavage of fibrinopeptide A from fibrinogen Aα-chains, followed by polymerization and cross-linkage to form thick fibrin bundles and complex branched clot network (8).
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
Frierson et al., Charlottesville, United States. In Lancet Oncol, 2006
A prominent polypeptide from the diagnostic pattern for urothelial carcinoma was identified as fibrinopeptide A-a known biomarker of ovarian cancer and gastric cancer.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Anderson et al., Boston, United States. In Jama, 1998
Neither treatment changed fibrinopeptide A or prothrombin fragment 1 and 2. CONCLUSIONS: Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.
Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease.
Dawes et al., Edinburgh, United Kingdom. In Lancet, 1993
We studied patients with intermittent claudication to see if the progression of peripheral arterial disease and the risks of coronary events could be predicted by baseline packed cell volume, plasma fibrinogen, blood and plasma viscosites, von Willebrand factor antigen, cross-linked fibrin degradation products (XLFDP), urinary fibrinopeptide A, and plasma leucocyte elastase.
Fibrinopeptide A and sudden coronary death.
Crompton et al., In Lancet, 1984
Fibrinopeptide A (FPA) concentrations were measured in blood taken by direct cardiac puncture from 31 patients who had died suddenly of ischaemic heart disease (IHD) and from 8 patients who had died suddenly of other causes.
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.
Forbes et al., In Lancet, 1983
Plasma levels of beta-thromboglobulin (BTG) and fibrinopeptide A (FPA), markers of platelet alpha-granule release and thrombin generation respectively, were measured in 27 subjects with transient cerebral ischaemic attacks (TIA), 43 age-matched controls, and 32 young controls.
share on facebooktweetadd +1mail to friends